Health News from Medical News Today: Phase II Study Results - E7080 Has Objective Response Rate Of 59% In Radioiodine (RAI)-Refractory Differentiated Thyroid Cancer

Health News from Medical News Today Latest Health News and Medical News posted throughout the day, every day. Phase II Study Results - E7080 Has Objective Response Rate Of 59% In Radioiodine (RAI)-Refractory Differentiated Thyroid Cancer 1 Jun 2011, 6:00 pm Preliminary results of a Phase II study to be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting showed that Eisai's E7080 (lenvatinib [USAN]) demonstrated an Objective Response Rate (ORR) of 59% (34/58, 95% CI:45 - 71),[2] based on an updated investigator assessment, in patients with advanced radioiodine (RAI)-refractory differentiated thyroid cancer (DTC).[1] These results will be presented during an ASCO oral session on June 6, 2011... You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed.